Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 0.49 |
| ▸ | HTR2A | P28223 | 11/20 | 0.49 |
| ▸ | DRD2 | P14416 | 7/20 | 0.45 |
| ▸ | DRD1 | P21728 | 7/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5506007 | 0.90 | OPRM1 (0.60) | OPRM1HTR2ADRD2DRD1SLC6A4 | |
| SCHEMBL30579711 | 0.90 | OPRM1 (0.60) | OPRM1HTR2ADRD2DRD1SLC6A4 | |
| SCHEMBL22023339 | 0.90 | OPRM1 (0.60) | OPRM1HTR2ADRD2DRD1SLC6A4 | |
| SCHEMBL5636917 | 0.82 | HTR2A (0.56) | OPRM1HTR2ADRD2DRD1SLC6A4 | |
| SCHEMBL6622170 | 0.82 | HTR2A (0.56) | OPRM1HTR2ADRD2DRD1SLC6A4 | |
| SCHEMBL5513380 | 0.82 | HTR2A (0.56) | OPRM1HTR2ADRD2DRD1SLC6A4 | |
| SCHEMBL5507337 | 0.82 | HTR2A (0.35) | OPRM1HTR2ADRD2DRD1SLC6A4 | |
| SCHEMBL5421686 | 0.81 | CCR3 (0.54) | HTR2ASLC6A4HTR2C | |
| SCHEMBL5421689 | 0.81 | CCR3 (0.54) | HTR2ASLC6A4HTR2C | |
| SCHEMBL22121768 | 0.78 | HTR2A (0.55) | OPRM1HTR2ADRD2DRD1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39680-E1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-06-05 | — | — | US | disclosed |
| US-7183282-B2 | Substituted heterocycle fused γ-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-02-27 | — | — | US | disclosed |
| US-20060148808-A1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2006-07-06 | — | — | US | disclosed |
| US-7071186-B2 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA CO. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20040220178-A1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-04 | — | — | US | disclosed |
| EP-1189904-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040034015-A1 | Substituted heterocycle fused gamma-carbolines | ROBICHAUD ALBERT J (US) | 2004-02-19 | — | — | US | disclosed |
| US-6552017-B1 | As serotonin agonists and antagonists and are useful in the control or prophylaxis of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034015-A1 | Substituted heterocycle fused gamma-carbolines | HCRTR1, HTR2C, OPRK1 | OPRM1 19/4885HTR2A 30/4885DRD2 16/4885 |
| US-20060148808-A1 | Substituted heterocycle fused gamma-carbolines | HTR2B, HTR1B, HTR3B | OPRM1 39/4885HTR2A 17/4885DRD2 11/4885 |
| US-20040220178-A1 | Substituted heterocycle fused gamma-carbolines | HCRTR1, HTR2C, OPRK1 | OPRM1 19/4885HTR2A 30/4885DRD2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.